New Delhi: Glenmark Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market Desonide Ointment, used to treat skin problems, in the American market.
Glenmark Pharmaceuticals Inc, a subsidiary of the company, has received final approval from the US Food and Drug Administration (USFDA) for Desonide ointment, the company said in a statement.
The Mumbai-based company’s product is the generic version of Perrigo New York Inc’s Desonide Ointment.
As per the latest IMS Health sales data, the product had annual sales of around USD 23.4 million.
Glenmark s current portfolio consists of 124 products authorized for distribution in the US marketplace and 62 ANDAs pending approval with the USFDA.
Latest posts by Ruby Khatun (see all)
- JnJ faulty hip implants case: CIC directs RTI disclosure of records - September 10, 2018
- Max Bupa launches WeCare initiative to aid Kerala flood victims - September 10, 2018
- Opposing Online Pharmacies, 8.5 lakh chemists to call it a strike on September 28 - September 9, 2018